课题基金 / 基金详情

CORE--CLINICAL

CORE--CLINICAL
核心--临床
批准号:
6932654
负责人:
ELAINE R. PESKIND
金额:
$47.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-05-01 至 2010-04-30

项目摘要

项目成果

ELAINE R. PESKIND的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
With the dramatic expansion and increased methodological sophistication in neurodegenerative dementia research, demands on the Clinical Core for clearly defined samples of persons with AD and related dementias, mild cognitive impairment (MCI), Lewy body spectrum disease, and age-matched controls have become more complex. A sample of subjects appropriate for one type of investigation (such as a clinical treatment outcome trial) is often not appropriate for other types of studies (for example, a case-control epidemiologic study or genetic linkage analysis). Still other types of samples are needed for training clinicians to manage the multiple clinical problems expressed during the course of dementia. To meet these multiple demands, the Clinical Core has developed and will continue to provide multiple samples of AD patients, non-AD dementia patients, MCI, and normal healthy control subjects suitable for supporting the subject recruitment needs of a broad range of research and clinical training in neurodegenerative dementias. The Clinical Core will continue to include probable AD and nondemented older controls selected for maximum appropriateness for participation in clinical studies. To comply with NIA guidance to focus on earlier stages of AD and the transition from normal aging, we will focus on increasing subject samples with early AD, MCI, and cognitively normal older controls. In addition, subjects with non-AD neurodegenerative dementing disorders and Lewy body spectrum disease will be recruited and followed in the Clinical Core. Clinical Core personnel support and interact with population-based cohorts of late life dementia and normal control subjects appropriate for epidemiologic studies and which provide additional sources for accession of postmortem brain tissue. Clinical Core personnel will continue to collect cerebrospinal fluid (CSF), plasma and serum on these subject samples and through collaborative efforts with multiple ADCs, continue to expand the large UW ADRC CSF bank to support the search for biomarkers for diagnosis and monitoring disease progression of dementing disorders. Through all these subject populations, subjects, biological fluid samples, and data are provided to meet the research needs of ADRC investigators, other appropriate investigators in the broader University of Washington research community, and investigators at other institutions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related Neuropathology
Mild TBI and Biomarkers of Neurodegeneration
  • 批准号:
    10490311
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2019
  • 负责人:
    ELAINE R. PESKIND
  • 依托单位:
Mild TBI and Biomarkers of Neurodegeneration
  • 批准号:
    10269890
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2019
  • 负责人:
    ELAINE R. PESKIND
  • 依托单位:
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease
  • 批准号:
    9265401
  • 项目类别:
  • 资助金额:
    $33.25万
  • 财政年份:
    2016
  • 负责人:
    ELAINE R. PESKIND
  • 依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2010
  • 负责人:
    梁胜
  • 依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2010
  • 负责人:
    郭亚芬
  • 依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究